Clinical OMICS

NOV-DEC 2018

Healthcare magazine for research scientists, labs, pathologists, hospitals, cancer centers, physicians and biopharma companies providing news articles, expert interviews and videos about molecular diagnostics in precision medicine

Issue link:

Contents of this Issue


Page 5 of 51

News November/December 2018 Clinical OMICs 4 Caris Locks Down $150M in New Funding Caris Life Sciences recently raised $150 million in growth capital in the form of senior secured debt and convertible notes from TPG Sixth Street Partners (TSSP), cash it will use, in part, to acceler- ate development of its Next Generation Profiling services. Next Generation Profiling is a tumor profiling approach that seeks not to de- fine a cancer by its site of origin, rather its unique molecular profile. The service combines the company's Caris Molecu- lar Intelligence and ADAPT Biotargeting System and its artificial intelligence ana- lytics engine DEAN. The service provides whole exome, whole transcriptome, and complete cancer proteome data for both clinician and drug developers. "With increasing demand for more precise and personalized treatment infor- mation to improve clinical outcomes and drug development, we believe this is the opportune time for Caris to complete a significant private capital raise and invest in our future growth," said Caris chairman and CEO David D. Halbert. n Quanterix' Test Links Soccer Headers with Concussions Biomarker analysis company Quanterix said researchers have shown a link be- tween heading a soccer ball and an increase in a protein biomarker associated with traumatic brain injury (TBI). The research, published in BMJ Open Sport & Exercise Medicine, used the company's Simoa technology and for the first time suggest athletic activities previously thought safe may cause brain injury. Led by Dr. Henrik Zetterberg at the University of Gothenburg, Sweden, the study ex- amined 11 male college soccer players who were asked to perform a series of headers. Researchers found elevated levels of the neurofilament light protein one hour after the players headed the ball, and those levels remained elevated even a month later. " This research adds to the growing body of evidence that the neurofilament light chain biomarker has promise as an objective indicator of brain damage and could play a role in improving player safety in the future," said Kevin Hrusovsky, CEO of Quanterix. n ViewStock / Getty Images NIH Expands Undiagnosed Diseases Network The NIH awarded research grants to five academic medical centers to create new clinical sites, in an expansion of its Undi- agnosed Diseases Network (UDN) that will include a new metabolomics core, and in- creased model organism capabilities. The five new clinical sites are: Children's Hospital of Philadelphia and the Hospital of University of Pennsylvania; University of Miami School of Medicine; University of Utah, Salt Lake City; University of Wash- ington School of Medicine, Seattle, and Seattle Children's Hospital; and Washing- ton University in St. Louis. The grants are intended to help the new sites improve and accelerate the diagno- sis of rare and undiagnosed conditions, the agency said—and were made as part of the second phase of the UDN, to which the NIH has committed a total of approxi- mately $100 million over four years n CIPhotos / Getty Images gerenme / Getty Images

Articles in this issue

Links on this page

Archives of this issue

view archives of Clinical OMICS - NOV-DEC 2018